T
Trevi Therapeutics, Inc.
TRVI · NASDAQ · Healthcare · 2.6B
Closing price
$13.19
+2.85% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
—
Price / net assetsP/B
10.4×
Enterprise value / EBITDAEV/EBITDA
-44.4×
Free cash flow yieldFCF yield
-2.2%
Return on equityROE
-23.3%
Operating margin
—
Net debt / EBITDAbalance-sheet strength
0.4×
Interest coverage
—
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.